Compare NTLA & RBCAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | RBCAA |
|---|---|---|
| Founded | 2014 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2016 | 1998 |
| Metric | NTLA | RBCAA |
|---|---|---|
| Price | $11.36 | $91.43 |
| Analyst Decision | Buy | |
| Analyst Count | 20 | 0 |
| Target Price | ★ $23.11 | N/A |
| AVG Volume (30 Days) | ★ 4.9M | 89.0K |
| Earning Date | 11-17-2026 | 10-23-2026 |
| Dividend Yield | N/A | ★ 2.13% |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | $67,671,000.00 | ★ $417,495,000.00 |
| Revenue This Year | N/A | $1.02 |
| Revenue Next Year | $143.36 | $4.64 |
| P/E Ratio | ★ N/A | $120.49 |
| Revenue Growth | ★ 16.92 | 8.50 |
| 52 Week Low | $7.95 | $63.97 |
| 52 Week High | $18.48 | $102.22 |
| Indicator | NTLA | RBCAA |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 52.08 |
| Support Level | $11.26 | $92.23 |
| Resistance Level | $13.50 | $93.83 |
| Average True Range (ATR) | 0.81 | 2.35 |
| MACD | 0.05 | 0.17 |
| Stochastic Oscillator | 51.49 | 59.15 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.